Ticker: ABSI

Snapshot - Absci Corporation (NASDAQ: ABSI) Quick take: Absci is ramping R&D and advancing its AI-driven drug-creation platform (ABS‑101 entered Phase 1 in May 2025) while revenue from partner programs has fallen and losses/cash burn remain material. Key points & statistics (facts from the 10‑Q) ...